Cargando…

Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms

Though pancreatic cancer is uncommon, with an age-adjusted annual incidence of 12.9 cases per 100,000 person-years, it is considered a refractory cancer due to the mortality of 11.0 per 100,000 person-years. To efficiently identify patients with potentially surgically-curable pancreatic cancer, high...

Descripción completa

Detalles Bibliográficos
Autor principal: Honda, Kazufumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108558/
https://www.ncbi.nlm.nih.gov/pubmed/35491769
http://dx.doi.org/10.3233/CBM-210198
_version_ 1784708731710210048
author Honda, Kazufumi
author_facet Honda, Kazufumi
author_sort Honda, Kazufumi
collection PubMed
description Though pancreatic cancer is uncommon, with an age-adjusted annual incidence of 12.9 cases per 100,000 person-years, it is considered a refractory cancer due to the mortality of 11.0 per 100,000 person-years. To efficiently identify patients with potentially surgically-curable pancreatic cancer, high-risk individuals (HRIs) for pancreatic cancer should be identified by easily and minimally invasive methods from the general population. We have identified unique processing patterns in the C-terminal amino acids of apolipoprotein A2 homodimer in the blood of patients with pancreatic cancer and in HRIs, and we called them apoA2-isoforms (apoA2-i). We then established an enzyme-linked immunosorbent assay (ELISA) to measure circulating apoA2-i in the blood stream. The diagnostic accuracy of apoA2-i to distinguish pancreatic cancer HRIs was verified by several retrospective studies, blind testing with the National Cancer Institute (NCI) Early Detection Research Network (EDRN), a prospective study with prediagnostic samples organized by the European Prospective Investigation into Cancer and Nutrition (EPIC) study, and the prospective screening study of pancreatic cancer in Kobe. The apoA2-i blood test is a potential biomarker to identify HRIs and the curative stage of pancreatic cancer in the general population.
format Online
Article
Text
id pubmed-9108558
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-91085582022-05-18 Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms Honda, Kazufumi Cancer Biomark Research Article Though pancreatic cancer is uncommon, with an age-adjusted annual incidence of 12.9 cases per 100,000 person-years, it is considered a refractory cancer due to the mortality of 11.0 per 100,000 person-years. To efficiently identify patients with potentially surgically-curable pancreatic cancer, high-risk individuals (HRIs) for pancreatic cancer should be identified by easily and minimally invasive methods from the general population. We have identified unique processing patterns in the C-terminal amino acids of apolipoprotein A2 homodimer in the blood of patients with pancreatic cancer and in HRIs, and we called them apoA2-isoforms (apoA2-i). We then established an enzyme-linked immunosorbent assay (ELISA) to measure circulating apoA2-i in the blood stream. The diagnostic accuracy of apoA2-i to distinguish pancreatic cancer HRIs was verified by several retrospective studies, blind testing with the National Cancer Institute (NCI) Early Detection Research Network (EDRN), a prospective study with prediagnostic samples organized by the European Prospective Investigation into Cancer and Nutrition (EPIC) study, and the prospective screening study of pancreatic cancer in Kobe. The apoA2-i blood test is a potential biomarker to identify HRIs and the curative stage of pancreatic cancer in the general population. IOS Press 2022-04-18 /pmc/articles/PMC9108558/ /pubmed/35491769 http://dx.doi.org/10.3233/CBM-210198 Text en © 2022 – The authors. Published by IOS Press. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Honda, Kazufumi
Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms
title Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms
title_full Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms
title_fullStr Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms
title_full_unstemmed Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms
title_short Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms
title_sort risk stratification of pancreatic cancer by a blood test for apolipoprotein a2-isoforms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108558/
https://www.ncbi.nlm.nih.gov/pubmed/35491769
http://dx.doi.org/10.3233/CBM-210198
work_keys_str_mv AT hondakazufumi riskstratificationofpancreaticcancerbyabloodtestforapolipoproteina2isoforms